Pharmaron Beijing Co., Ltd. (3759.HK)

HKD 13.76

(-1.57%)

Net Income Summary of Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd.'s latest annual net income in 2023 was 1.6 Billion CNY , up 16.48% from previous year.
Pharmaron Beijing Co., Ltd.'s latest quarterly net income in 2024 Q2 was 882.84 Million CNY , up 282.92% from previous quarter.
Pharmaron Beijing Co., Ltd. reported an annual net income of 1.37 Billion CNY in 2022, down -17.24% from previous year.
Pharmaron Beijing Co., Ltd. reported an annual net income of 1.66 Billion CNY in 2021, up 41.68% from previous year.
Pharmaron Beijing Co., Ltd. reported a quarterly net income of 230.55 Million CNY for 2024 Q1, down -50.1% from previous quarter.
Pharmaron Beijing Co., Ltd. reported a quarterly net income of 308.39 Million CNY for 2024 Q3, down -65.07% from previous quarter.

Annual Net Income Chart of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Historical Annual Net Income of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Year	Net Income	Net Income Growth
2023	1.6 Billion CNY	16.48%
2022	1.37 Billion CNY	-17.24%
2021	1.66 Billion CNY	41.68%
2020	1.17 Billion CNY	114.25%
2019	547.19 Million CNY	61.31%
2018	339.22 Million CNY	46.94%
2017	230.85 Million CNY	30.49%
2016	176.91 Million CNY	139.57%
2015	73.84 Million CNY	251.73%
2014	20.99 Million CNY	0.0%

Year	Net Income	Net Income Growth
2024 Q2	882.84 Million CNY	282.92%
2024 Q1	230.55 Million CNY	-50.1%
2024 Q3	308.39 Million CNY	-65.07%
2023 Q1	348.25 Million CNY	-15.78%
2023 FY	1.6 Billion CNY	16.48%
2023 Q4	462.05 Million CNY	30.92%
2023 Q3	352.94 Million CNY	-19.39%
2023 Q2	437.83 Million CNY	25.72%
2022 Q1	249.08 Million CNY	-59.89%
2022 FY	1.37 Billion CNY	-17.24%
2022 Q4	413.49 Million CNY	10.07%
2022 Q3	375.67 Million CNY	11.69%
2022 Q2	336.34 Million CNY	35.03%
2021 FY	1.66 Billion CNY	41.68%
2021 Q4	620.96 Million CNY	30.67%
2021 Q3	475.22 Million CNY	48.99%
2021 Q1	245.87 Million CNY	-35.86%
2021 Q2	318.96 Million CNY	29.73%
2020 Q2	377.44 Million CNY	271.8%
2020 Q1	101.51 Million CNY	-53.6%
2020 Q3	310.08 Million CNY	-17.85%
2020 FY	1.17 Billion CNY	114.25%
2020 Q4	383.33 Million CNY	23.62%
2019 Q1	54.39 Million CNY	-49.91%
2019 FY	547.19 Million CNY	61.31%
2019 Q4	218.81 Million CNY	30.98%
2019 Q3	167.05 Million CNY	56.23%
2019 Q2	106.92 Million CNY	96.57%
2018 Q1	40.82 Million CNY	-45.95%
2018 FY	339.22 Million CNY	46.94%
2018 Q4	108.59 Million CNY	0.49%
2018 Q3	108.06 Million CNY	32.86%
2018 Q2	81.33 Million CNY	99.23%
2017 Q4	75.53 Million CNY	0.0%
2017 FY	230.85 Million CNY	30.49%
2016 FY	176.91 Million CNY	139.57%
2015 FY	73.84 Million CNY	251.73%
2014 FY	20.99 Million CNY	0.0%

Peer Net Income Comparison of Pharmaron Beijing Co., Ltd.

Name	Net Income	Net Income Difference
Uni-Bio Science Group Limited	70.87 Million HKD	-2159.01%
CK Life Sciences Int'l., (Holdings) Inc.	17.25 Million HKD	-9181.716%